Molnupiravir: an oral treatment to add to the COVID-19 arsenal


The Therapeutic Goods Administration (TGA) has granted provisional approval for two new oral medications that are indicated for use in mild-to-moderate COVID-19 infections to prevent disease progression and hospitalisations. What are these medications and where do they fit into treatment guidelines? By Kayla Lee BPharmSci, MPharm, pharmacist and managing partner, Capital Chemist Braidwood Learning Objectives

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?